BioXcel Therapeutics (BTAI) Earnings Analysis

BioXcel Therapeutics (BTAI) has no confirmed upcoming earnings date. Last quarter (2026-05-15) it beat with EPS -0.54 USD vs -0.59 USD est (+8.5%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -0.13.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BTAI next report earnings?

No confirmed upcoming earnings date is currently scheduled for BTAI. This page updates as the calendar is published.

BTAI earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.54 USD-0.59 USD+8.5%Beat
2026-03-26-0.58 USD-0.34 USD-70.6%Miss
2025-05-12-1.5 USD-2.72 USD+44.9%Beat
2024-11-14-5.12 USD-8 USD+36%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

BTAI valuation and analyst view

Trailing P/E-0.13
Trailing EPS-6.17087 USD
Price / book-0.10
Dividend yield0.00%
Market cap0.03B
Analyst consensusBuy (8 buy / 6 hold / 1 sell)

Related research pages

Frequently asked questions

When is BioXcel Therapeutics (BTAI)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for BTAI. This page updates as the calendar is published.

Did BTAI beat earnings last quarter?

In its 2026-05-15 report, BTAI posted EPS of -0.54 USD versus a -0.59 USD estimate — a beat of 8.5%.

What is BTAI's earnings track record?

Over the last 4 reported quarters with consensus data, BTAI beat estimates 3 times (75%).

What is BTAI's current P/E ratio and EPS?

BTAI trades at a trailing P/E of -0.13 on trailing EPS of -6.170871559633028 USD.

What do analysts rate BTAI?

Analyst consensus is "Buy" across 15 ratings (0 strong buy, 8 buy, 6 hold, 1 sell, 0 strong sell).